Tessa Romero
Stock Analyst at J.P. Morgan
(4.54)
# 1,027
Out of 4,994 analysts
207
Total ratings
51%
Success rate
16.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Rated: Buy | $70 | $51.19 | +36.75% | 12 | Sep 21, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $82 | $39.09 | +109.77% | 17 | Sep 19, 2026 | |
| BHVN Biohaven | Reiterated: Buy | n/a | $14.85 | - | 15 | Sep 13, 2026 | |
| DYN Dyne Therapeutics | Downgraded: Sell | $10 | $17.14 | -41.66% | 15 | Sep 8, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | n/a | $67.59 | - | 34 | Aug 20, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Buy | $53 → $60 | $44.51 | +34.80% | 22 | Aug 20, 2026 | |
| SEPN Septerna | Reiterated: Buy | $38 → $48 | $40.38 | +18.87% | 4 | Aug 19, 2026 | |
| EYPT EyePoint | Downgraded: Hold | n/a | $4.07 | - | 8 | Aug 17, 2026 | |
| OCS Oculis Holding AG | Rated: Buy | $23 → $20 | $10.71 | +86.74% | 5 | Aug 14, 2026 | |
| UPB Upstream Bio | Reiterated: Hold | $8 → $9 | $5.49 | +63.93% | 11 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $3.82 | +135.60% | 2 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $4.07 | +121.13% | 4 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $31 | $34.97 | -11.35% | 17 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $25.67 | - | 3 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $22.39 | +87.58% | 2 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $0.7785 | - | 5 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $3.35 | - | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $34 | $26.41 | +28.74% | 19 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.54 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $4.02 | n/a | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.33 | n/a | 4 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $10 | $8.93 | n/a | 2 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $48.82 | n/a | 1 | Nov 9, 2020 |
Scholar Rock Holding
Sep 21, 2026
Rated: Buy
Price Target: $70
Current: $51.19
Upside: +36.75%
Xenon Pharmaceuticals
Sep 19, 2026
Reiterated: Buy
Price Target: $82
Current: $39.09
Upside: +109.77%
Biohaven
Sep 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.85
Upside: -
Dyne Therapeutics
Sep 8, 2026
Downgraded: Sell
Price Target: $10
Current: $17.14
Upside: -41.66%
Cytokinetics
Aug 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $67.59
Upside: -
Edgewise Therapeutics
Aug 20, 2026
Rated: Buy
Price Target: $53 → $60
Current: $44.51
Upside: +34.80%
Septerna
Aug 19, 2026
Reiterated: Buy
Price Target: $38 → $48
Current: $40.38
Upside: +18.87%
EyePoint
Aug 17, 2026
Downgraded: Hold
Price Target: n/a
Current: $4.07
Upside: -
Oculis Holding AG
Aug 14, 2026
Rated: Buy
Price Target: $23 → $20
Current: $10.71
Upside: +86.74%
Upstream Bio
Aug 14, 2026
Reiterated: Hold
Price Target: $8 → $9
Current: $5.49
Upside: +63.93%
Jun 29, 2026
Reiterated: Buy
Price Target: $9
Current: $3.82
Upside: +135.60%
Jun 25, 2026
Reiterated: Buy
Price Target: $9
Current: $4.07
Upside: +121.13%
Jun 11, 2026
Rated: Hold
Price Target: $31
Current: $34.97
Upside: -11.35%
Jun 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.67
Upside: -
Jun 8, 2026
Reiterated: Buy
Price Target: $42
Current: $22.39
Upside: +87.58%
May 26, 2026
Reiterated: Sell
Price Target: n/a
Current: $0.7785
Upside: -
Apr 2, 2026
Reiterated: Sell
Price Target: n/a
Current: $3.35
Upside: -
Mar 4, 2026
Rated: Buy
Price Target: $31 → $34
Current: $26.41
Upside: +28.74%
Nov 18, 2025
Reiterated: Hold
Price Target: n/a
Current: $3.54
Upside: -
Oct 23, 2024
Downgraded: Sell
Price Target: n/a
Current: $4.02
Upside: n/a
Oct 18, 2024
Reiterated: Hold
Price Target: n/a
Current: $3.33
Upside: n/a
Jul 13, 2022
Downgraded: Hold
Price Target: $22 → $10
Current: $8.93
Upside: n/a
Nov 9, 2020
Downgraded: Hold
Price Target: n/a
Current: $48.82
Upside: n/a